Quarterly Result19 May 2026, 12:04 pm
Kwality Pharma FY26 Revenue Up ~36% YoY to ₹503 Cr
AI Summary
Kwality Pharmaceuticals Ltd (KPL) reported its highest-ever quarterly and annual revenues in FY26. Q4 FY26 revenue was ₹157.11 crore, up 35.8% YoY. FY26 consolidated revenue reached ₹503 crore, a ~36% increase from ₹370 crore in FY25. EBITDA margins improved to 24%, a 200 bps expansion. Profit After Tax (PAT) for FY26 stood at ₹67.34 crore, up ~69% YoY, with PAT margins expanding to 13.4%. ICRA upgraded KPL's credit rating to BBB+ from B+.
Key Highlights
- Q4 FY26 revenue grew 35.8% YoY to ₹157.11 crore.
- FY26 consolidated revenue increased by ~36% YoY to ₹503 crore.
- EBITDA margins improved to 24%, a 200 bps increase from FY25.
- FY26 PAT grew by ~69% YoY to ₹67.34 crore.
- ICRA upgraded KPL's credit rating to BBB+ from B+.
Price Impact
More from KPL